

AMENDMENTS TO THE SPECIFICATION

In the specification, at page 139, lines 4-11, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

The following patents and patent applications are specifically incorporated herein by reference for the purposes of even further supplementing the present teachings regarding the preparation and use of immunotoxins directed against expressed, adsorbed, induced or localized markers of tumor vasculature: U.S. Patents Nos. 5,855,866; 5,776,427; 5,863,538; 5,660,827; 5,855,866; ~~and~~ 5,877,289; 6,004,554; 5,965,132; 6,051,230; 6,093,399; 6,004,555; and 6,036,955 and U.S. ~~Applications~~ Application Serial No. 07/846,349; ~~08/295,868 (Patent No. 5,____,____; Issue Fee paid); 08/350,212 (Patent No. 5,____,____; Issue Fee paid); 08/457,869 (Notice of Allowance Received); 08/482,369 (U.S. Patent 5,____,____; Issue Fee paid); 08/487,427 (U.S. Patent 5,____,____; Issue Fee paid); and 08/479,727 (U.S. Patent 5,____,____; Issue Fee paid).~~

In the specification, at page 139, lines 18-22, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

The following patents and patent applications are specifically incorporated herein by reference for the purposes of even further supplementing the present teachings regarding the preparation and use of tumor stromal targeting agents: U.S. Patent ~~No.~~ Nos. 5,877,289, 6,093,399; 6,004,555; and 6,036,955 and U.S. ~~Applications~~ Serial Nos. ~~08/482,369 (U.S. Patent 5,____,____; Issue Fee paid); 08/487,427 (U.S. Patent 5,____,____; Issue Fee paid); and 08/479,727 (U.S. Patent 5,____,____; Issue Fee paid).~~

In the specification, at page 142, lines 11-16, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

For tumor targeting and treatment with immunotoxins, the following patents and patent applications are specifically incorporated herein by reference for the purposes of even further supplementing the present teachings regarding anticellular and cytotoxic agents: U.S. Patents Nos. 5,855,866; 5,776,427; 5,863,538; ~~and 5,660,827; 6,004,554; 5,965,132; and 6,051,230;~~ and U.S. Applications Application Serial No. 07/846,349; ~~08/295,868 (Patent No. 5,____,____; Issue Fee paid); 08/350,212 (Patent No. 5,____,____; Issue Fee paid); and 08/457,869 (Notice of Allowance Received).~~

In the specification, at page 143, lines 1-7, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

Tumor targeting and treatment with coaguligands is described in the following patents and patent applications, each of which are specifically incorporated herein by reference for the purposes of even further supplementing the present teachings regarding coaguligands and coagulation factors: U.S. Patent Nos. 5,855,866; ~~and 5,877,289; 5,965,132; 6,093,399; 6,004,555; and 6,036,955;~~ and U.S. Application Serial No. 07/846,349 ~~U.S. Applications Serial Nos. 07/846,349 ; 08/350,212 (Patent No. 5,____,____; Issue Fee paid); 08/482,369 (U.S. Patent 5,____,____; Issue Fee paid); 08/487,427 (U.S. Patent 5,____,____; Issue Fee paid); and 08/479,727 (U.S. Patent 5,____,____; Issue Fee paid).~~

In the specification, at page 143, lines 19-25, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

The preparation of immunotoxins is generally well known in the art (see, *e.g.*, U.S. Patent 4,340,535, incorporated herein by reference). Each of the following patents and patent applications are further incorporated herein by reference for the purposes of even further supplementing the present teachings regarding immunotoxin generation, purification and use: U.S. Patents Nos. 5,855,866; 5,776,427; 5,863,538; ~~and 5,660,827; 6,004,554; and 5,965,132~~ and U.S. Applications Application Serial No. 07/846,349; ~~08/295,868 (Patent No. 5,____,____; Issue Fee paid); 08/350,212 (Patent No. 5,____,____; Issue Fee paid); and 08/457,869 (Notice of Allowance Received).~~

In the specification, at page 144, lines 16-21, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

A variety of chemotherapeutic and other pharmacological agents can also be successfully conjugated to antibodies or targeting ligands. Exemplary antineoplastic agents that have been conjugated to antibodies include doxorubicin, daunomycin, methotrexate and vinblastine. Moreover, the attachment of other agents such as neocarzinostatin, macromycin, trenimon and α -amanitin has been described (see U.S. Patent No. 5,855,866; and Patent No. ~~5,____,____~~ (~~Application Serial No. 08/350,212, Issue Fee paid~~) 5,965,132 and references incorporated therein).

In the specification, at page 146, lines 14-20, please delete the existing paragraph and replace the deleted paragraph with the following paragraph after making the following changes:

The following patents and patent applications are each incorporated herein by reference for the purposes of even further supplementing the present teachings regarding coaguligand

preparation, purification and use, including bispecific antibody coaguligands: U.S. Patent Nos. 5,855,866; ~~and 5,877,289; 5,965,132; 6,093,399; 6,004,555; and 6,036,955;~~ and U.S. Applications Serial Nos. 07/846,349; 08/350,212 (Patent No. 5,____,____; Issue Fee paid); and 08/273,567; ~~08/482,369; 08/485,482; and 08/472,631 (U.S. Patent 5,____,____; Issue Fee paid);~~ 08/487,427 (U.S. Patent 5,____,____; Issue Fee paid); ~~and 08/479,727 and 08/481,904 (U.S. Patent 5,____,____; Issue Fee paid).~~